Edition:
United States

Laboratory Corporation of America Holdings (LH.N)

LH.N on New York Stock Exchange

143.18USD
1:39pm EDT
Change (% chg)

$0.27 (+0.19%)
Prev Close
$142.91
Open
$142.69
Day's High
$143.22
Day's Low
$142.47
Volume
45,655
Avg. Vol
199,084
52-wk High
$145.00
52-wk Low
$113.46

Latest Key Developments (Source: Significant Developments)

Labcorp's zero coupon convertible subordinated notes due 2021 to accrue contingent interest
Monday, 13 Mar 2017 08:45am EDT 

Laboratory Corporation Of America Holdings : Labcorp's zero coupon convertible subordinated notes due 2021 to accrue contingent interest . Labcorp - for period of March 12, 2017 to Sept 11, 2017, its zero coupon convertible subordinated notes due 2021 will accrue contingent cash interest . Labcorp-Contingent cash interest to be at rate of no less than 0.125% of average market price of zero coupon note for five trading days ended march 8 . Labcorp - contingent cash interest has been determined to be approximately $2.39 per note .Labcorp - payment of contingent cash interest is expected to be made on September 12, 2017.  Full Article

Labcorp to acquire pathology associates medical laboratories from Providence Health & Services and Catholic Health Initiatives
Thursday, 23 Feb 2017 04:30pm EST 

Laboratory Corporation of America Holdings : Labcorp to acquire pathology associates medical laboratories from Providence Health & Services and Catholic Health Initiatives . Labcorp says other terms of transactions were not disclosed .Labcorp says there will be no changes to operations or services at PAML or joint ventures until applicable transaction is complete.  Full Article

Laboratory Corporation Of America Q4 adjusted EPS $2.15
Thursday, 16 Feb 2017 06:58am EST 

Laboratory Corporation Of America Holdings : Laboratory Corporation Of America Holdings announces record 2016 fourth quarter and full year results and provides 2017 guidance . Q4 earnings per share $1.75 . Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $9.35 to $9.75 . Q4 adjusted earnings per share $2.15 . Q4 revenue $2.4 billion versus I/B/E/S view $2.35 billion . Laboratory Corporation Of America Holdings- 2017 free cash flow guidance of $925 million to $975 million, up 3% to 9% over 2016 . Sees FY 17 net revenue growth of 4.5% to 6.5% over 2016 . Labcorp - on track to deliver cost synergies of $100 million related to acquisition of covance through three-year period ending in 2017 . Laboratory Corporation Of America Holdings - backlog at end of year was $4.9 billion . Laboratory Corporation Of America Holdings - expects approximately $2.0 billion of backlog to convert into revenue in next twelve months .Sees FY 2017 adjusted earnings per share $9.35 to $9.75.  Full Article

Labcorp to acquire assets of Mount Sinai Health System clinical Outreach Laboratories
Tuesday, 10 Jan 2017 08:30am EST 

Laboratory Corporation Of America Holdings : Terms of transaction were not disclosed. . Labcorp to acquire assets of Mount Sinai Health System Clinical Outreach Laboratories .Transaction, which has already received clearance under Hart-Scott-Rodino act expected to close in Q1 of 2017.  Full Article

Laboratory Corporation of America reports Q3 EPS $1.71
Wednesday, 26 Oct 2016 06:53am EDT 

Laboratory Corporation Of America Holdings : Laboratory Corporation Of America® holdings announces 2016 third quarter results and updates 2016 guidance . Q3 adjusted earnings per share $2.25 . Q3 earnings per share $1.71 . Q3 revenue $2.4 billion versus I/B/E/S view $2.38 billion . Q3 earnings per share view $2.29 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $8.70 to $8.90 . Sees FY 2016 net revenue growth of 10.0 pct to 11.0 pct over 2015 net revenue of $8.51 billion . Sees 2016 net revenue growth of 10.0 pct to 11.0 pct over 2015 net revenue of $8.51 billion . Laboratory Corporation Of America sees FY 2016 free cash flow (operating cash flow less capital expenditures) of $840 million to $880 million .2016 outlook for net revenue growth includes impact from about 60 basis points of negative currency.  Full Article

Shore Capital Partners announces sale of Clearpath Diagnostics to LabCorp
Tuesday, 4 Oct 2016 06:30am EDT 

Shore Capital Partners: Shore Capital Partners announces sale of Clearpath Diagnostics .Terms of transaction were not disclosed.  Full Article

Oxford Immunotec announces favorable recommendation by the magistrate judge
Thursday, 1 Sep 2016 07:03am EDT 

Oxford Immunotec Global PLC : Oxford Immunotec announces favorable recommendation by the magistrate judge in patent infringement litigation . Says recommendation denying in substantial part defendants' motion to dismiss company's claims . Patent infringement lawsuit against Qiagen Inc, Quest Diagnostics Inc and Laboratory Corporation of America Holdings .Says recommendation should now "allow company to press forward with its case against three defendants".  Full Article

Labcorp's acquisition of Sequenom clears antitrust review
Tuesday, 23 Aug 2016 08:45am EDT 

Laboratory Corporation Of America Holdings : Labcorp's acquisition of Sequenom clears antitrust review .Scott-Rodino antitrust improvements act of 1976 applicable to acquisition of Sequenom Inc by co has expired.  Full Article

Labcorp to acquire Sequenom
Wednesday, 27 Jul 2016 07:47am EDT 

Laboratory Corporation Of America Holdings : Labcorp announces agreement to acquire sequenom . Deal for an equity value of $302 million . Deal for an equity value of $302 million . Would acquire all of outstanding shares of sequenom in a cash tender offer for $2.40 per share . Labcorp announces agreement to acquire sequenom . Deal has total enterprise value of approximately $371 million . Deal has total enterprise value of approximately $371 million, including net indebtedness . Says board of directors of sequenom, having determined that offer and merger are advisable . Jp morgan is acting as financial advisor to sequenom in connection with transaction, and cooley llp is providing legal advice .Says barclays is acting as financial advisor to labcorp, and hogan lovells is providing legal advice.  Full Article

LabCorp reports Q2 adjusted earnings per share of $2.31
Wednesday, 27 Jul 2016 07:46am EDT 

Laboratory Corporation Of America Holdings : Laboratory corporation of america holdings says raises 2016 guidance . Sees 2016 net revenue growth of 9.5% to 10.5% over 2015 . Sees 2016 net revenue growth in labcorp diagnostics of 4.5 percent to 5.5 percent . Laboratory corporation of america® holdings announces 2016 second quarter results and raises 2016 guidance . Q2 adjusted earnings per share $2.31 . Q2 earnings per share $1.91 . Q2 revenue $2.4 billion versus i/b/e/s view $2.33 billion . Q2 earnings per share view $2.30 -- Thomson Reuters I/B/E/S . Sees fy 2016 adjusted earnings per share $8.60 to $8.95 . Sees 2016 free cash flow (operating cash flow less capital expenditures) of $900 million to $950 million . Fy2016 earnings per share view $8.79, revenue view $9.35 billion -- Thomson Reuters I/B/E/S . Laboratory corporation of america holdings sees 2016 net revenue growth of 9.5% to 10.5% .Laboratory corporation of america holdings says organic revenue growth in quarter, excluding currency, was 6.4%.  Full Article

More From Around the Web